About the Company
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $JNCE News
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Boxed, Inc. (NYSE: BOXD) shares fell 9.8% to $ ... get started now. This article Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ...
Jounce Therapeutics Inc.
Rates under 4% came and went during the Covid pandemic, but home prices soared. Here's what buyers and sellers face as the housing season ramps up.
Gilead licenses Jounce immunotherapy for $800m
Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million. The drug, JTX-1811, is a monoclonal antibody designed to ...
Drug developer Redx Pharma's $425m merger with Jounce Therapeutics off after takeover agreed
The deal was first announced last month when the boards of Alderley Park-based Redx Pharma and Jounce Therapeutics both ... would have been known as Redx Inc and be solely listed on Nasdaq in ...
Redx and Jounce Announce Recommended Business Combination
Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007 ...
Omega Therapeutics Inc OMGA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...
Leap Therapeutics Inc LPTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
OTLK Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead ...
Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
Warning! GuruFocus has detected 8 Warning Signs with MCRB. On March 5, 2024, Seres Therapeutics Inc (NASDAQ:MCRB) released its 8-K filing, announcing the fourth quarter and full year financial ...
TG Therapeutics Inc (TGTX) Announces Fourth Quarter and Full Year 2023 Financial Results
Warning! GuruFocus has detected 4 Warning Signs with TGTX. On February 28, 2024, TG Therapeutics Inc (NASDAQ:TGTX) released its 8-K filing, detailing the financial outcomes for the fourth quarter ...
Jounce Therapeutics
This page shows the latest Jounce Therapeutics news and features for those working in and with pharma, biotech and healthcare. In November 2020, Jounce Therapeutics also announced that it would not ...
Loading the latest forecasts...